The Next 5 Years in Obesity Medicine: What to Watch

The expected timeline

2026-2027: Retatrutide approval likely. Eli Lilly's triple GIP/GLP-1/glucagon agonist. Phase 3 readouts ongoing; ~24% weight loss in Phase 2. Will likely become the deepest available weight-loss agent if approved.

2026-2028: CagriSema approval. Novo Nordisk's fixed combination of cagrilintide (amylin) + semaglutide. First fixed-combination obesity medication with two mechanism arms. Phase 3 staggered readouts through 2025-2026.

2027-2028: Bimagrumab + tirzepatide approval likely. Pharmacological muscle preservation combined with GLP-1 weight loss. Phase 3 ongoing.

2026-2030: Multiple dual/triple agonist competitors. Survodutide (Boehringer Ingelheim/Zealand), mazdutide (Innovent/Lilly, approved in China), pemvidutide (Altimmune), efinopegdutide (Merck), HRS9531 (Hengrui), and others entering or completing Phase 3.

2027-2029: Higher-dose oral semaglutide for obesity. Novo Nordisk's OASIS program tests oral semaglutide at higher doses than current Rybelsus for obesity indication.

2028-2030: Small-molecule GLP-1 receptor agonists. Orforglipron (Eli Lilly) and others — oral non-peptide GLP-1 agonists. Different manufacturing economics could substantially affect pricing.

2029-2030: Generic exenatide and liraglutide. The earliest GLP-1 medications begin going generic in various markets. Semaglutide generics likely 2031-2033.

Retatrutide: the next dominant molecule

Retatrutide's expected approval represents the natural next step after tirzepatide. Triple agonism produces deeper weight loss; the magnitude advantage (Phase 2 showed 24% vs. tirzepatide's 21%) is meaningful at the population level.

Likely positioning post-approval: first-line for severe obesity (BMI >40 or significant comorbidities), step-up therapy for patients plateaued on tirzepatide, NAFLD/MASH indication possible alongside obesity. Cost likely similar to tirzepatide at $1,000-1,500/month cash pricing.

The retatrutide story will continue beyond initial approval as cardiovascular outcomes data from TRIUMPH outcomes trial accumulates. Likely positive cardiovascular benefits given class trajectory; specific magnitude vs. semaglutide unclear.

The combination paradigm

The most consequential conceptual shift over the next 5 years: from single-molecule therapy to combination therapy.

Three combination approaches in late-stage development:

1. GLP-1 + Amylin (CagriSema): Different appetite-regulation circuits, additive effect
2. GLP-1 + Anti-myostatin (Bimagrumab + Tirzepatide): Fat loss + muscle preservation
3. Triple agonism within single molecule (Retatrutide): GLP-1 + GIP + glucagon

By 2030, obesity treatment may not be "pick a GLP-1" but "pick a combination based on what your specific patient needs." Patient with sarcopenia: GLP-1 + bimagrumab. Patient with NAFLD: GLP-1 + glucagon component. Patient who plateaued on monotherapy: amylin combination. Etc.

Oral GLP-1 expansion

The oral GLP-1 space is becoming more interesting:

Higher-dose oral semaglutide: Novo Nordisk's OASIS program tests oral semaglutide at doses higher than current Rybelsus (which goes to 14 mg daily). Higher-dose oral semaglutide could produce weight loss comparable to lower-dose injectable, expanding the patient population willing to use oral medication.

Orforglipron (Eli Lilly): Non-peptide small-molecule GLP-1 receptor agonist. Different manufacturing economics — no peptide synthesis costs, potentially lower pricing. Phase 3 trials ongoing.

Danuglipron (Pfizer): Was a small-molecule GLP-1 contender; development was paused in 2024 due to tolerability issues. Pfizer subsequently shifted focus to other candidates.

Implications: Oral options expand the patient population willing to use obesity medications. Cost dynamics may shift if small-molecule alternatives are substantially cheaper than peptide injectables.

NAFLD/MASH-specific developments

Resmetirom (Rezdiffra) became the first FDA-approved MASH medication in 2024 — a thyroid hormone receptor-β agonist, not a peptide. The NAFLD/MASH space is rapidly developing with several peptide candidates:

Efinopegdutide (Merck): GLP-1/glucagon dual agonist with positive Phase 2b NASH data showing hepatic fat reduction superior to semaglutide alone.

Retatrutide for MASH: Phase 2 hepatic data supports potential NAFLD/MASH indication alongside obesity.

Pemvidutide: GLP-1/glucagon dual with NASH-specific development.

By 2028-2030, MASH treatment may include several peptide-based options alongside resmetirom and emerging FXR agonists, providing combination approaches for liver-disease patients.

What this means for current patients

Several practical implications:

Don't wait for future options. Current GLP-1 medications are highly effective and have substantial safety data. Starting therapy now and switching/adding as new options become available is the right approach.

Build sustainable habits. Resistance training, protein intake, and structured eating remain the behavioral foundation regardless of which pharmacological approach you're on now or future. These habits matter more, not less, as treatment options expand.

Expect personalization. By 2028-2030, treatment selection will increasingly be matched to patient profiles. Information about your specific clinical situation (CVD, NAFLD, sarcopenia risk, family history) will guide combination choice.

Cost will remain a question. The newer combinations and triple agonists will likely cost more, not less, than current options for several years. Insurance coverage patterns will be substantial determinants of access.

Watch the cardiovascular outcomes data. The cardiovascular evidence base is the strongest argument for long-term GLP-1 therapy. As cardiovascular outcomes data accumulates for newer molecules, the value proposition becomes clearer.

The bigger picture

Obesity is transitioning from a behavior-only problem to a chronic disease with effective pharmacological treatment — comparable to how cardiovascular disease was reframed through the statin era and how diabetes was reframed through insulin and now GLP-1 expansion. The next 5 years will likely complete this transition.

By 2030, the standard expectation for obesity treatment may be 25-30%+ weight loss with combination therapy, sustained as long as therapy continues, with substantial reductions in cardiovascular events, renal disease, NAFLD/MASH progression, and obesity-related cancers. This is a fundamental change from the pre-2018 era.

The remaining questions over this period will be less about whether the medications work and more about access, affordability, long-term outcomes, and how to integrate pharmacological treatment with sustained behavioral support.